Titrating-Dose of Lonafarnib in Combination With Ritonavir
Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
A phase 2, open-label study to evaluate the safety, tolerability, pharmacokinetics, and
pharmacodynamic activity of titrating-dose lonafarnib in combination with ritonavir in
patients chronically infected with hepatitis delta virus